Another arrow.....
A new Phase 1 study suggests that combining Cabozantinib with Atezolizumab could improve outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC).
While overall tumor response rates were similar between monotherapy and combination therapy, patients receiving both drugs had longer-lasting responses, improved PSA control, and better survival outcomes. Notably, in patients with liver metastases, median survival nearly tripled (14.7 vs. 5.0 months).
Side effects were manageable, with no treatment-related deaths. These findings highlight the potential of combination therapy to enhance immune response and extend survival, particularly in high-risk patients.
SBRT Added to Standard Tx Boosts Outcomes in Oligometastatic PCa - ARTO II~ Improved response & PFS compared to SOC, MedPage Today, 09/27/23
EXTEND - Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer
